Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BEKYREE vs ATROMID-S
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BEKYREE (balcinrenone) is a selective mineralocorticoid receptor antagonist that binds to the mineralocorticoid receptor, inhibiting aldosterone-mediated sodium reabsorption and reducing inflammation and fibrosis in the kidney and heart.
Inhibits hepatic triglyceride synthesis and increases lipoprotein lipase activity, leading to reduced VLDL and triglycerides.
Treatment of chronic kidney disease in patients with type 2 diabetes,Reduction of albuminuria in chronic kidney disease
Type III hyperlipoproteinemia,Hypertriglyceridemia (Fredrickson types IV and V) not responsive to diet
1 mg/kg intravenously every 4 weeks; maximum dose 100 mg.
500 mg to 1 g orally twice daily. Maximum dose 2 g/day.
Terminal elimination half-life: 12 hours (range 10-14 h); prolonged in renal impairment (up to 30 h in Cr Cl <30 m L/min)
Terminal elimination half-life is 6-8 hours in patients with normal renal function; may be prolonged to 12-24 hours in renal impairment.
Primarily metabolized by CYP3A4; minor contributions from CYP2C8 and CYP2C9.
Hepatic via glucuronidation and oxidation; major metabolite is clofibric acid.
Renal: 70% (unchanged drug), Biliary/fecal: 30% (metabolites and unchanged drug)
Primarily renal excretion as glucuronide conjugates; approximately 60-70% of the dose is excreted in urine, 20-30% in feces via biliary elimination.
95% bound to albumin and alpha-1-acid glycoprotein
>95% bound to plasma proteins, primarily albumin.
0.8-1.2 L/kg (indicates extensive tissue distribution)
0.11-0.14 L/kg; low Vd indicates limited extravascular distribution, consistent with high protein binding.
Oral: 60% (range 50-70%; first-pass metabolism reduces bioavailability)
Oral: approximately 60-70% due to first-pass metabolism; administered as clofibrate (prodrug) which is hydrolyzed to active clofibric acid.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m²). Not recommended for severe renal impairment (e GFR <30 m L/min/1.73 m²) due to lack of data.
GFR 30-59 m L/min: 500 mg twice daily. GFR 15-29 m L/min: 250 mg twice daily. GFR <15 m L/min: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: 0.5 mg/kg intravenously every 4 weeks; Child-Pugh C: not recommended.
Child-Pugh Class B or C: avoid use or reduce dose by at least 50%; not recommended in severe hepatic impairment.
Safety and efficacy not established in pediatric patients under 18 years.
Not recommended; safety and efficacy not established in pediatric patients.
No specific dose adjustment required; consider age-related renal function and comorbidities.
Start at lower end of dosing range (500 mg twice daily). Monitor renal function; adjust dose based on GFR.
None.
None
Hyperkalemia: Monitor serum potassium regularly; avoid use with strong CYP3A4 inhibitors or potassium supplements.,Acute kidney injury: May occur; assess renal function before initiation.,Adrenal insufficiency: Not studied in patients with adrenal disorders.,Pregnancy: Limited data; avoid use unless benefit outweighs risk.
Hepatotoxicity,Cholelithiasis,Renal impairment dose adjustment,Rhabdomyolysis risk with statins,Malignancy risk (hepatic, GI)
Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin),Serum potassium >5.0 m Eq/L at initiation,e GFR <15 m L/min/1.73 m² (not studied),Hypersensitivity to balcinrenone or any excipient
Hypersensitivity to clofibrate,Active liver disease,Severe renal dysfunction,Primary biliary cirrhosis,Pregnancy
No known food interactions. Avoid grapefruit juice if patient is on concurrent CYP3A4 substrates (though bevacizumab is not metabolized by CYP enzymes). Maintain adequate hydration to reduce risk of constipation, a common side effect.
High-fat meals may reduce absorption; consistent timing of administration with food is recommended. Grapefruit juice may increase drug levels; avoid excessive intake. Alcohol may exacerbate hepatotoxicity.
First trimester: Avoid use due to potential teratogenicity (limited human data, animal studies show risk). Second/Third trimester: Use only if benefit outweighs risk; monitor for fetal growth restriction and oligohydramnios.
FDA Pregnancy Category C. First trimester: Potential for teratogenicity based on animal studies showing skeletal and visceral anomalies. Human data limited; use only if benefit outweighs risk. Second and third trimesters: May cause fetal harm due to placental transfer and potential for reduced fetal growth.
No human data on excretion in breast milk. M/P ratio unknown. Avoid breastfeeding due to potential for adverse effects in nursing infant.
Excreted into breast milk in low amounts; M/P ratio not established. Due to potential for serious adverse effects in infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
No specific dose adjustments recommended based on pharmacokinetic changes. However, monitor therapeutic effect and adjust dose as needed based on clinical response and tolerability.
No specific dosing adjustments recommended due to lack of data. However, pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) may necessitate careful monitoring and empiric dose adjustments based on clinical response and adverse effects.
BEKYREE (bevacizumab-awwb) is a biosimilar to bevacizumab. Monitor for hypertension, proteinuria, and bleeding. Discontinue 28 days prior to elective surgery. Avoid use in patients with recent hemoptysis or serious hemorrhage. Infusion reactions may occur; premedicate with antihistamines and acetaminophen as per protocol.
ATROMID-S (clofibrate) is a fibric acid derivative primarily indicated for hyperlipidemia but its use is now limited due to increased non-cardiovascular mortality and cholelithiasis risk. Monitor liver function and prothrombin time (potentiates warfarin). Not first-line; consider statins or fibrates like fenofibrate.
Tell your doctor if you have a history of bleeding problems, blood clots, or recent surgery.,Avoid taking aspirin or NSAIDs unless prescribed by your doctor, as they increase bleeding risk.,Report any unusual bleeding, coughing up blood, or black/tarry stools immediately.,Women of childbearing age must use effective contraception during therapy and for 6 months after last dose.,Do not breastfeed during treatment and for 6 months after the last dose.,Monitor for signs of hypertension (severe headache, blurred vision) and proteinuria (foamy urine).
Take with meals to reduce gastrointestinal upset.,Report unexplained muscle pain, tenderness, or weakness; may indicate myopathy.,Avoid alcohol as it may increase liver enzyme elevations.,Notify your doctor if you develop gallstones symptoms (e.g., right upper abdominal pain, nausea).,Use effective contraception as clofibrate may cause fetal harm.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BEKYREE vs ATROMID-S, answered by our medical review team.
BEKYREE is a Antilipemic Agent that works by BEKYREE (balcinrenone) is a selective mineralocorticoid receptor antagonist that binds to the mineralocorticoid receptor, inhibiting aldosterone-mediated sodium reabsorption and reducing inflammation and fibrosis in the kidney and heart.. ATROMID-S is a Antilipemic Agent that works by Inhibits hepatic triglyceride synthesis and increases lipoprotein lipase activity, leading to reduced VLDL and triglycerides.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BEKYREE and ATROMID-S depend on the specific clinical indication. These are both Antilipemic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BEKYREE is: 1 mg/kg intravenously every 4 weeks; maximum dose 100 mg.. The standard adult dose of ATROMID-S is: 500 mg to 1 g orally twice daily. Maximum dose 2 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BEKYREE and ATROMID-S in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BEKYREE is classified as Category C. First trimester: Avoid use due to potential teratogenicity (limited human data, animal studies show risk). Second/Third trimester: Use only if benefit outweighs risk; monitor for f. ATROMID-S is classified as Category C. FDA Pregnancy Category C. First trimester: Potential for teratogenicity based on animal studies showing skeletal and visceral anomalies. Human data limited; use only if benefit out. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.